Brevan Howard Capital Management’s Nurix Therapeutics NRIX Stock Holding History

Brevan Howard Capital Management’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$411K	Buy	26,501 +5,821	+28%	+$96.5K	﹤0.01%	1424
2025 Q4	$392K	Sell	20,680 -54,104	-72%	-$777K	﹤0.01%	1227
2025 Q3	$691K	Buy	74,784 +11,913	+19%	+$124K	﹤0.01%	1110
2025 Q2	$716K	Buy	+62,871	New	+$679K	﹤0.01%	1215
2025 Q1	–	Sell	-21,495	Closed	-$405K	–	1363
2024 Q4	$405K	Buy	+21,495	New	+$493K	﹤0.01%	683
2024 Q1	–	Sell	-11,068	Closed	-$114K	–	1240
2023 Q4	$114K	Buy	+11,068	New	+$75.9K	﹤0.01%	943

Other funds holding NRIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Brevan Howard Capital Management's NRIX Position: Q1 2026 in Review

Brevan Howard Capital Management increased its Nurix Therapeutics (NRIX) stake by 28% in Q1 2026, buying an estimated $96.5K and bringing the position to 26,501 shares worth $411K. The position accounts for ﹤0.01% of the portfolio, ranked #1424.

Brevan Howard Capital Management first reported a position in NRIX in Q4 2023 and has held it in 6 quarters since. The position peaked at $716K in Q2 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

Brevan Howard Capital Management held 26,501 shares of Nurix Therapeutics worth $411K as of Q1 2026.
Brevan Howard Capital Management bought 5,821 Nurix Therapeutics shares in Q1 2026, an estimated $96.5K.
Nurix Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q1 2026, its #1424 holding.
Brevan Howard Capital Management first reported a position in Nurix Therapeutics in Q4 2023 and has held it in 6 quarters since.
Brevan Howard Capital Management's Nurix Therapeutics position peaked at $716K in Q2 2025.
195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.